 | |
| Clinical data | |
|---|---|
| Other names | 2-O-Methoxymethylsalvinorin B; 2-MMSB |
| Drug class | κ-Opioid receptor agonist;Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H30O8 |
| Molar mass | 434.485 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Salvinorin B methoxymethyl ether, also known as2-O-methoxymethylsalvinorin B (2-MMSB) is asemisyntheticanalogue of the natural productsalvinorin A which is used inscientific research.[1][2][3]
It has a longerduration of action of around 2 to 3 hours,[3] compared to less than 30 minutes for salvinorin A,[4] and has increasedaffinity andpotency at theκ-opioidreceptor. It is prepared fromsalvinorin B.[5] Thecrystal structure is almost superimposable with that of salvinorin A.[6] Structures bound to the κ-opioid receptor have also been reported.[7]
Salvinorin B methoxymethyl ether has aKi of 0.60 nM at the κ opioid receptor,[8] and is around five times more potent than salvinorin A in animal studies, although it is still only half as potent as its ethoxymethyl etherhomologue,salvinorin B ethoxymethyl ether (2-O-ethoxymethylsalvinorin B; 2-EMSB; "symmetry").[8][9][10]
The drug was encountered online as a noveldesigner drug in 2020.[3]
